var data={"title":"Infection due to coagulase-negative staphylococci: Treatment","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Infection due to coagulase-negative staphylococci: Treatment</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/contributors\" class=\"contributor contributor_credentials\">JoAnn M Tufariello, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/contributors\" class=\"contributor contributor_credentials\">Franklin D Lowy, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/contributors\" class=\"contributor contributor_credentials\">Daniel J Sexton, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/contributors\" class=\"contributor contributor_credentials\">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 09, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Coagulase-negative staphylococci (CoNS) are part of the normal flora of human skin [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/1\" class=\"abstract_t\">1</a>]. These organisms have relatively low virulence but are increasingly recognized as agents of clinically significant infection of the bloodstream and other sites. Risk factors for CoNS infection include the presence of foreign devices (such as intravascular catheters) and immune compromise.</p><p>Issues related to antimicrobial resistance and treatment of CoNS infections will be reviewed here. The epidemiology, microbiology, pathogenesis, and clinical manifestations of CoNS are discussed separately. (See <a href=\"topic.htm?path=infection-due-to-coagulase-negative-staphylococci-epidemiology-microbiology-and-pathogenesis\" class=\"medical medical_review\">&quot;Infection due to coagulase-negative staphylococci: Epidemiology, microbiology, and pathogenesis&quot;</a> and <a href=\"topic.htm?path=infection-due-to-coagulase-negative-staphylococci-clinical-manifestations\" class=\"medical medical_review\">&quot;Infection due to coagulase-negative staphylococci: Clinical manifestations&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6286044\"><span class=\"h1\">ANTIMICROBIAL SUSCEPTIBILITY</span></p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h2\">Methicillin</span></p><p class=\"headingAnchor\" id=\"H6285704\"><span class=\"h3\">Microbiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Resistance to penicillin among coagulase-negative staphylococci (CoNS) approaches 90 to 95 percent. Resistance to methicillin and semisynthetic penicillins has been observed in more than 80 percent of CoNS isolates [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/2\" class=\"abstract_t\">2</a>]; these isolates are often resistant to multiple classes of antibiotics in addition to beta-lactams. An important exception is <em>Staphylococcus lugdunensis</em>, which is unique among the CoNS by virtue of its susceptibility to a wide range of antimicrobials. (See <a href=\"topic.htm?path=staphylococcus-lugdunensis\" class=\"medical medical_review\">&quot;Staphylococcus lugdunensis&quot;</a>.)</p><p>The genes responsible for resistance are often found on plasmids, facilitating horizontal exchange of resistance genes among strains. The <em>mecA</em> gene encoding a low-affinity penicillin-binding protein (PBP 2a) is responsible for mediating methicillin or <a href=\"topic.htm?path=oxacillin-drug-information\" class=\"drug drug_general\">oxacillin</a> resistance in CoNS, as in <em>Staphylococcus aureus</em> [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/3\" class=\"abstract_t\">3</a>]. It is part of a mobile genetic element called SCC<em>mec </em>(staphylococcal cassette chromosome). This resistance is usually heterotypic, since only a minority of the bacterial population (as few as one in 10<sup>3</sup> or 10<sup>6</sup> organisms) expresses the resistant phenotype; this makes detection of resistance especially challenging [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/4\" class=\"abstract_t\">4</a>]. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-microbiology\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA): Microbiology&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6285711\"><span class=\"h3\">Epidemiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of studies describing the acquisition and spread of resistant organisms have been performed in patients undergoing cardiac surgery [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/5-9\" class=\"abstract_t\">5-9</a>]. Preoperatively, cardiac surgery patients generally have CoNS skin isolates that are susceptible to methicillin; resistant clones appear to emerge with selective pressure of perioperative antibiotic prophylaxis [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/5\" class=\"abstract_t\">5</a>]. This observation may reflect selection of resistant organisms from the patient's preoperative flora <span class=\"nowrap\">and/or</span> postoperative acquisition from the nosocomial environment [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/6-8,10\" class=\"abstract_t\">6-8,10</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one study including 29 patients undergoing cardiac surgery who underwent preoperative sampling of the nares, subclavian, and inguinal areas, methicillin-resistant CoNS were detected in rare numbers from at least one site in 75 percent of patients [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/6\" class=\"abstract_t\">6</a>]. Postoperatively, more than half of the sites with baseline colonization contained high levels of methicillin-resistant staphylococci. Antibiograms and plasmid profile patterns suggested that these resistant organisms were derived from the small number of resistant organisms present preoperatively [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/6,8\" class=\"abstract_t\">6,8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another study, approximately one-third of patients had methicillin-resistant staphylococci cultured from the skin preoperatively (no patients were colonized with organisms resistant to both methicillin and <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a>); 10 days postoperatively, &gt;90 percent of patients harbored CoNS resistant to both methicillin and gentamicin, often from multiple skin sites [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/8\" class=\"abstract_t\">8</a>]. Plasmid analysis revealed the postoperative isolates differed from the preoperative isolates, indicating possible acquisition from the environment. In addition, the skin of unit staff working was found to be colonized with staphylococci resistant to both methicillin and gentamicin.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Investigation of an outbreak of postoperative wound infection and endocarditis due to a single strain of methicillin-resistant <em>S. epidermidis</em> revealed the same strain to be present on the hands of one of the five surgeons; no further cases were reported after additional infection control measures relating to handwashing practices were implemented [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/10\" class=\"abstract_t\">10</a>].</p><p/><p>A number of more recent studies have demonstrated the spread of single clones and molecular clusters of drug-resistant CoNS in neonatal intensive care units (ICUs) and other hospital settings [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/11-15\" class=\"abstract_t\">11-15</a>]. In a study of <em>S. epidermidis</em> colonization in ventricular-assist device recipients at four medical centers, the isolates were found to fit into one of seven clones that were all highly antibiotic resistant, suggesting that these clones may be prevalent in health care settings [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/16\" class=\"abstract_t\">16</a>]. In contrast, community-associated isolates of <em>S. epidermidis</em> demonstrate a low level of methicillin resistance and are genetically diverse [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/17\" class=\"abstract_t\">17</a>].</p><p>The factors contributing to the spread of drug-resistant CoNS in hospital environments remain to be fully elucidated; in addition to the selective pressure of antibiotic exposure, features of the pathogen (such as its capacity to adhere to foreign materials and to elaborate biofilms) may play roles, as may issues of infection control such as hand hygiene and disinfection of equipment and surfaces [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=infection-due-to-coagulase-negative-staphylococci-epidemiology-microbiology-and-pathogenesis\" class=\"medical medical_review\">&quot;Infection due to coagulase-negative staphylococci: Epidemiology, microbiology, and pathogenesis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6285719\"><span class=\"h3\">Laboratory detection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reliable detection of methicillin resistance is critical to facilitate initiation of appropriate antimicrobial therapy [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/18\" class=\"abstract_t\">18</a>]. Breakpoints for determining the susceptibility of CoNS to <a href=\"topic.htm?path=oxacillin-drug-information\" class=\"drug drug_general\">oxacillin</a> were revised by the Clinical and Laboratory Standards Institute (CLSI) in 2007 [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/19\" class=\"abstract_t\">19</a>]. The methicillin minimum inhibitory concentration (MIC) breakpoints for CoNS (except <em>S. lugdunensis</em>) are &le;0.25 <span class=\"nowrap\">mg/L</span> for susceptibility to oxacillin and &ge;0.5 <span class=\"nowrap\">mg/L</span> for resistance to oxacillin according to CLSI guidelines [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/20\" class=\"abstract_t\">20</a>], while an oxacillin MIC breakpoint of &ge;0.25 <span class=\"nowrap\">mg/L</span> indicates resistance according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/21\" class=\"abstract_t\">21</a>]. For disk susceptibility testing, the <a href=\"topic.htm?path=cefoxitin-drug-information\" class=\"drug drug_general\">cefoxitin</a> disk is the preferred method to detect CoNS oxacillin susceptibility [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/22\" class=\"abstract_t\">22</a>].</p><p>Accurate detection of resistance in the clinical laboratory requires the use of measures to enhance expression of this phenotype, including [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/23\" class=\"abstract_t\">23</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Incubation at a lower temperature (30 to 35&ordm;C)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Incubation for a prolonged period of time (24 to 48 hours)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Medium with an increased sodium chloride content (2 percent NaCl)</p><p/><p>If the results remain uncertain, detection of the <em>mecA</em> gene using DNA hybridization or polymerase chain reaction (PCR) techniques can be pursued [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/24-26\" class=\"abstract_t\">24-26</a>]. In addition, a latex agglutination test developed for detection of PBP 2a of methicillin-resistant <em>S. aureus</em> (MRSA-Screen) has been investigated for its applicability in identifying methicillin resistance in a variety of species of CoNS [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/27-30\" class=\"abstract_t\">27-30</a>]. This rapid assay has shown 98 percent sensitivity and high specificity in the hands of some investigators for <em>S. epidermidis</em> [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/27\" class=\"abstract_t\">27</a>], although non&ndash;<em>S. epidermidis</em> strains occasionally yielded false-positive results.</p><p>An isolate determined to be methicillin resistant should be considered resistant to all beta-lactam antibiotics, including beta-lactamase inhibitor combinations, cephalosporins, and carbapenems (regardless of in vitro susceptibility results) [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/31\" class=\"abstract_t\">31</a>]. <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">Ceftaroline</a> is an exception; it is a cephalosporin that retains activity against methicillin-resistant strains.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Vancomycin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There have been case reports of CoNS with reduced susceptibility to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>: two in patients on continuous ambulatory peritoneal dialysis (CAPD) and one in a patient with febrile neutropenia on empiric antimicrobial therapy [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/32-34\" class=\"abstract_t\">32-34</a>]. The MICs in these isolates were 8 to 16 <span class=\"nowrap\">mg/L</span>. One of these reports documented the emergence of relative vancomycin resistance (with a stepwise increase in the MIC from 2 to 8 <span class=\"nowrap\">mg/L)</span> in a patient treated with vancomycin for <em>Staphylococcus haemolyticus</em> peritonitis [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/32\" class=\"abstract_t\">32</a>].</p><p>The mechanism of glycopeptide resistance among staphylococci appears to be associated with alterations in cell wall metabolism, including cell wall thickening [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/35-38\" class=\"abstract_t\">35-38</a>]. Increased cell wall thickness has also been observed in various CoNS clinical strains that demonstrate heterogeneous resistance to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/39\" class=\"abstract_t\">39</a>]. (See <a href=\"topic.htm?path=staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin\" class=\"medical medical_review\">&quot;Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin&quot;</a>.)</p><p>CoNS glycopeptide resistance appears to occur in the form of heteroresistant subpopulations of organisms. Therefore, accurate detection in the laboratory can be difficult. As an example, one group reported the isolation of vancomycin-intermediate <em>S. epidermidis</em> from peritoneal fluid specimens of a patient undergoing CAPD who developed peritonitis [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/40\" class=\"abstract_t\">40</a>]. The primary isolate had a <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> MIC of 12 to 16 <span class=\"nowrap\">mg/L</span>. However, subculture and testing by a variety of methods demonstrated strains that appeared to be susceptible to vancomycin. The authors proposed that the phenotype of intermediate vancomycin resistance may have been expressed by only a small subpopulation of organisms in the original specimen, which may have been lost or diluted upon subculture (perhaps due to loss of selective pressure of the antibiotic). To screen for potential vancomycin resistance in CoNS, some investigators have used induction methods, such as placement of an <a href=\"topic.htm?path=aztreonam-drug-information\" class=\"drug drug_general\">aztreonam</a> disk on vancomycin-salt agar to demonstrate growth of satellite colonies [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/41\" class=\"abstract_t\">41</a>]. (See <a href=\"topic.htm?path=overview-of-antibacterial-susceptibility-testing#H1897544320\" class=\"medical medical_review\">&quot;Overview of antibacterial susceptibility testing&quot;, section on 'Heteroresistance'</a>.)</p><p>MIC cutoffs for CoNS <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> testing are susceptible if &le;4 <span class=\"nowrap\">mg/L,</span> intermediate if 8 to 16 <span class=\"nowrap\">mg/L,</span> and resistant if &ge;32 <span class=\"nowrap\">mg/L</span> according to CLSI [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/19\" class=\"abstract_t\">19</a>]. According to EUCAST guidelines, an MIC &gt;4 <span class=\"nowrap\">mg/L</span> indicates vancomycin resistance for CoNS [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/21\" class=\"abstract_t\">21</a>]. The vancomycin MIC breakpoints for CoNS differ from those of <em>S. aureus</em>. (See <a href=\"topic.htm?path=staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin\" class=\"medical medical_review\">&quot;Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6286944\"><span class=\"h2\">Other resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There have been an increasing number of reports of <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> resistance among CoNS, although this remains rare [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/42\" class=\"abstract_t\">42</a>]. One outbreak of colonization with linezolid-resistant CoNS was reported among 16 ICU patients over a six-month period. The resistant strains were isolated from several sites and contained the G2576T mutation conferring linezolid resistance. Nasal screening among ICU staff was negative. Institution and reinforcement of infection control procedures and restrictions on linezolid prescribing were successful in controlling the outbreak [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/43\" class=\"abstract_t\">43</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">TREATMENT</span></p><p class=\"headingAnchor\" id=\"H6286959\"><span class=\"h2\">Choice of therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The agent of choice for empiric treatment of infections due to coagulase-negative staphylococci (CoNS) is <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>; it is generally the mainstay of treatment for methicillin-resistant CoNS infections. In the setting of infection due to CoNS that is known to be methicillin susceptible (as confirmed by specialized testing such as a gene probe for the <em>mecA</em> gene), the preferred agent is <a href=\"topic.htm?path=nafcillin-drug-information\" class=\"drug drug_general\">nafcillin</a> or <a href=\"topic.htm?path=oxacillin-drug-information\" class=\"drug drug_general\">oxacillin</a>. If specialized testing is not available, vancomycin should be used because of the high frequency of methicillin-resistant strains and because of concerns about heteroresistance with CoNS.</p><p>Additional agents with potential activity against CoNS include <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a>, <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a>, <a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">telavancin</a>, <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a>, <a href=\"topic.htm?path=quinupristin-and-dalfopristin-drug-information\" class=\"drug drug_general\">quinupristin-dalfopristin</a>, <a href=\"topic.htm?path=tedizolid-drug-information\" class=\"drug drug_general\">tedizolid</a>, <a href=\"topic.htm?path=oritavancin-drug-information\" class=\"drug drug_general\">oritavancin</a>, and <a href=\"topic.htm?path=dalbavancin-drug-information\" class=\"drug drug_general\">dalbavancin</a>. Linezolid has significant bacteriostatic activity against methicillin-resistant CoNS in vitro and has been used successfully in infected patients [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/44-46\" class=\"abstract_t\">44-46</a>]. Daptomycin and telavancin have excellent in vitro activity against staphylococci, although experience with clinical efficacy is limited [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/47-49\" class=\"abstract_t\">47-49</a>]. Ceftaroline has excellent in vitro activity against methicillin-resistant <em>S. aureus</em> (MRSA) and methicillin-susceptible <em>S. aureus</em>, but clinical data are limited [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/50,51\" class=\"abstract_t\">50,51</a>]. Ceftaroline has been used, both alone and in combination with daptomycin, as salvage therapy for persistent staphylococcal bacteremia, although experience is primarily with <em>S. aureus</em> and not with CoNS [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/52-54\" class=\"abstract_t\">52-54</a>]. Quinupristin-dalfopristin has in vitro activity against multiple-resistant CoNS [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/55-57\" class=\"abstract_t\">55-57</a>]. Other agents with potential efficacy include teicoplanin (a glycopeptide antibiotic), <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a>, and <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/58-61\" class=\"abstract_t\">58-61</a>]. Antistaphylococcal agents are discussed further separately. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia&quot;</a>.)</p><p>For treatment of some deep-seated infections, addition of <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> <span class=\"nowrap\">and/or</span> <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> may be warranted [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/62\" class=\"abstract_t\">62</a>]. Gentamicin is rapidly bactericidal for CoNS, but its clinical utility is limited by resistance (60 to 70 percent of isolates in some studies) [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/63,64\" class=\"abstract_t\">63,64</a>]. More than 90 percent of CoNS isolates remain susceptible to rifampin [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/4\" class=\"abstract_t\">4</a>], although this drug must be used in combination with another antibiotic since resistance develops rapidly with rifampin monotherapy [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/5,65\" class=\"abstract_t\">5,65</a>].</p><p>For treatment of prosthetic device infections such as prosthetic valve endocarditis, <a href=\"topic.htm?path=oxacillin-drug-information\" class=\"drug drug_general\">oxacillin</a> or <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> plus <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> and <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> is appropriate [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/62\" class=\"abstract_t\">62</a>]. <a href=\"topic.htm?path=fusidic-acid-united-states-not-available-drug-information\" class=\"drug drug_general\">Fusidic acid</a> has been used in Europe, Australia, and Canada for the treatment of staphylococcal infections, most often skin infections [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/66\" class=\"abstract_t\">66</a>]; it is not available in the United States. Development of fusidic acid resistance has been observed, especially in the setting of monotherapy with a topical form of the drug [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/66\" class=\"abstract_t\">66</a>], and a substantial percentage of CoNS isolates exhibit fusidic acid resistance (approximately 10 to 40 percent in various studies) [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/1\" class=\"abstract_t\">1</a>]. A critical component of prosthetic device-related infections is device removal; it is highly unlikely that these infections can be successfully managed without removal of the device. In a limited number of circumstances (such as<em> </em>lack of alternative vascular access site), it may be necessary to attempt therapy without device removal.</p><p>Fluoroquinolones as monotherapy are generally not appropriate for treatment of infections due to CoNS; this is due to the relatively high level of resistance to these agents and to the emergence of resistance during therapy [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/67\" class=\"abstract_t\">67</a>]. In one study including more than 6000 CoNS isolates, substantial rates of <a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a> resistance (55 percent) were observed [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/2\" class=\"abstract_t\">2</a>]. Later-generation fluoroquinolones may have greater activity than earlier-generation agents and higher barriers to the development of resistance; however, evolving fluoroquinolone resistance among CoNS isolates has been observed, and the potential for emergence of resistance to the newer fluoroquinolone has been demonstrated in in vitro models simulating human pharmacodynamics [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/68-72\" class=\"abstract_t\">68-72</a>]. Fluoroquinolones are excreted in sweat, which may be associated with rapid emergence of resistance among CoNS comprising skin flora [<a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/73,74\" class=\"abstract_t\">73,74</a>].</p><p class=\"headingAnchor\" id=\"H6286966\"><span class=\"h2\">Duration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The duration of therapy depends on the clinical site of infection. Depending on the source, bacteremia in the absence of involvement of other sites may be treated for 7 to 14 days. Endocarditis must be considered in patients with sustained CoNS bacteremia and in the presence of a prosthetic valve. The duration of therapy for other forms of infection is discussed separately. (See <a href=\"topic.htm?path=treatment-of-intravascular-catheter-related-infections\" class=\"medical medical_review\">&quot;Treatment of intravascular catheter-related infections&quot;</a> and <a href=\"topic.htm?path=antimicrobial-therapy-of-native-valve-endocarditis\" class=\"medical medical_review\">&quot;Antimicrobial therapy of native valve endocarditis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6287571\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Coagulase-negative staphylococci (CoNS) are part of the normal flora of human skin. These organisms have relatively low virulence but are increasingly recognized as agents of clinically significant infection of the bloodstream and other sites. Risk factors for CoNS infection include indwelling foreign devices and immune compromise. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Resistance to methicillin and semisynthetic penicillins has been observed in more than 80 percent of coagulase-negative staphylococcal isolates. The genes responsible for resistance are often found on plasmids, facilitating the horizontal exchange of resistance genes among strains. The methicillin minimum inhibitory concentration (MIC) breakpoints for CoNS (except <em>Staphylococcus lugdunensis</em>) are &le;0.25 <span class=\"nowrap\">mg/L</span> for susceptibility to <a href=\"topic.htm?path=oxacillin-drug-information\" class=\"drug drug_general\">oxacillin</a> and &ge;0.5 <span class=\"nowrap\">mg/L</span> for resistance to oxacillin according to Clinical and Laboratory Standards Institute guidelines. (See <a href=\"#H2\" class=\"local\">'Methicillin'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There have been case reports of CoNS with reduced susceptibility to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>. CoNS glycopeptide resistance appears to occur in the form of heteroresistant subpopulations of organisms. Therefore, accurate detection in the laboratory can be difficult. The vancomycin MIC breakpoints for CoNS are susceptible if &le;4 <span class=\"nowrap\">mg/L,</span> intermediate if 8 to 16 <span class=\"nowrap\">mg/L,</span> and resistant if &ge;32 <span class=\"nowrap\">mg/L</span>. (See <a href=\"#H5\" class=\"local\">'Vancomycin'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The agent of choice for empiric treatment of infections due to CoNS is <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>; it is generally the mainstay of treatment for methicillin-resistant CoNS infections. In the setting of infection due to CoNS that is known to be methicillin susceptible, the preferred agent is <a href=\"topic.htm?path=nafcillin-drug-information\" class=\"drug drug_general\">nafcillin</a> or <a href=\"topic.htm?path=oxacillin-drug-information\" class=\"drug drug_general\">oxacillin</a>. Additional agents with potential activity against CoNS include <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a>, <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a>, <a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">telavancin</a>, <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a>, <a href=\"topic.htm?path=quinupristin-and-dalfopristin-drug-information\" class=\"drug drug_general\">quinupristin-dalfopristin</a>, <a href=\"topic.htm?path=tedizolid-drug-information\" class=\"drug drug_general\">tedizolid</a>, <a href=\"topic.htm?path=oritavancin-drug-information\" class=\"drug drug_general\">oritavancin</a>, and <a href=\"topic.htm?path=dalbavancin-drug-information\" class=\"drug drug_general\">dalbavancin</a>. (See <a href=\"#H6\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The duration of treatment of CoNS infection depends on the clinical site of infection. Bacteremia in the absence of involvement of other sites may be treated for 7 to 14 days. The duration of therapy for other forms of infection is discussed separately. (See <a href=\"topic.htm?path=treatment-of-intravascular-catheter-related-infections\" class=\"medical medical_review\">&quot;Treatment of intravascular catheter-related infections&quot;</a> and <a href=\"topic.htm?path=antimicrobial-therapy-of-native-valve-endocarditis\" class=\"medical medical_review\">&quot;Antimicrobial therapy of native valve endocarditis&quot;</a>.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/1\" class=\"nounderline abstract_t\">Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. Clin Microbiol Rev 2014; 27:870.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/2\" class=\"nounderline abstract_t\">Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 Suppl 2:S114.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/3\" class=\"nounderline abstract_t\">Ryffel C, Tesch W, Birch-Machin I, et al. Sequence comparison of mecA genes isolated from methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. Gene 1990; 94:137.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/4\" class=\"nounderline abstract_t\">Archer GL, Climo MW. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob Agents Chemother 1994; 38:2231.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/5\" class=\"nounderline abstract_t\">Archer GL, Armstrong BC. Alteration of staphylococcal flora in cardiac surgery patients receiving antibiotic prophylaxis. J Infect Dis 1983; 147:642.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/6\" class=\"nounderline abstract_t\">Kernodle DS, Barg NL, Kaiser AB. Low-level colonization of hospitalized patients with methicillin-resistant coagulase-negative staphylococci and emergence of the organisms during surgical antimicrobial prophylaxis. Antimicrob Agents Chemother 1988; 32:202.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/7\" class=\"nounderline abstract_t\">Archer GL, Dietrick DR, Johnston JL. Molecular epidemiology of transmissible gentamicin resistance among coagulase-negative staphylococci in a cardiac surgery unit. J Infect Dis 1985; 151:243.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/8\" class=\"nounderline abstract_t\">Archer GL. Alteration of cutaneous staphylococcal flora as a consequence of antimicrobial prophylaxis. Rev Infect Dis 1991; 13 Suppl 10:S805.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/9\" class=\"nounderline abstract_t\">Levy MF, Schmitt DD, Edmiston CE, et al. Sequential analysis of staphylococcal colonization of body surfaces of patients undergoing vascular surgery. J Clin Microbiol 1990; 28:664.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/10\" class=\"nounderline abstract_t\">Boyce JM, Potter-Bynoe G, Opal SM, et al. A common-source outbreak of Staphylococcus epidermidis infections among patients undergoing cardiac surgery. J Infect Dis 1990; 161:493.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/11\" class=\"nounderline abstract_t\">Foka A, Chini V, Petinaki E, et al. Clonality of slime-producing methicillin-resistant coagulase-negative staphylococci disseminated in the neonatal intensive care unit of a university hospital. Clin Microbiol Infect 2006; 12:1230.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/12\" class=\"nounderline abstract_t\">Krediet TG, Mascini EM, van Rooij E, et al. Molecular epidemiology of coagulase-negative staphylococci causing sepsis in a neonatal intensive care unit over an 11-year period. J Clin Microbiol 2004; 42:992.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/13\" class=\"nounderline abstract_t\">Liakopoulos V, Petinaki E, Efthimiadi G, et al. Clonal relatedness of methicillin-resistant coagulase-negative staphylococci in the haemodialysis unit of a single university centre in Greece. Nephrol Dial Transplant 2008; 23:2599.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/14\" class=\"nounderline abstract_t\">Monsen T, Karlsson C, Wistr&ouml;m J. Spread of clones of multidrug-resistant, coagulase-negative staphylococci within a university hospital. Infect Control Hosp Epidemiol 2005; 26:76.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/15\" class=\"nounderline abstract_t\">Widerstr&ouml;m M, Monsen T, Karlsson C, Wistr&ouml;m J. Molecular epidemiology of meticillin-resistant coagulase-negative staphylococci in a Swedish county hospital: evidence of intra- and interhospital clonal spread. J Hosp Infect 2006; 64:177.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/16\" class=\"nounderline abstract_t\">Gordon RJ, Miragaia M, Weinberg AD, et al. Staphylococcus epidermidis colonization is highly clonal across US cardiac centers. J Infect Dis 2012; 205:1391.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/17\" class=\"nounderline abstract_t\">Widerstr&ouml;m M, Wistr&ouml;m J, Ek E, et al. Near absence of methicillin-resistance and pronounced genetic diversity among Staphylococcus epidermidis isolated from healthy persons in northern Sweden. APMIS 2011; 119:505.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/18\" class=\"nounderline abstract_t\">Tenover FC, Jones RN, Swenson JM, et al. Methods for improved detection of oxacillin resistance in coagulase-negative staphylococci: results of a multicenter study. J Clin Microbiol 1999; 37:4051.</a></li><li class=\"breakAll\">National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Tenth Informational Supplement. NCCLS document M100-S17 vol. 27. No. 1, 2007. National Committee for Clinical Laboratory Standards, Wayne, PA.</li><li class=\"breakAll\">Clinical Laboratory and Standards Institute. http://clsi.org/ (Accessed on June 08, 2015).</li><li class=\"breakAll\">The European Committee on Antimicrobial Susceptibility Testing - EUCAST. http://www.eucast.org/ (Accessed on June 08, 2015).</li><li class=\"breakAll\">Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth Informational Supplement. CLSI document M100-S19; 29, Clinical and Laboratory Standards Institute, Wayne, PA 2009.</li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/23\" class=\"nounderline abstract_t\">Maranan MC, Moreira B, Boyle-Vavra S, Daum RS. Antimicrobial resistance in staphylococci. Epidemiology, molecular mechanisms, and clinical relevance. Infect Dis Clin North Am 1997; 11:813.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/24\" class=\"nounderline abstract_t\">Archer GL, Pennell E. Detection of methicillin resistance in staphylococci by using a DNA probe. Antimicrob Agents Chemother 1990; 34:1720.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/25\" class=\"nounderline abstract_t\">Ubukata K, Nakagami S, Nitta A, et al. Rapid detection of the mecA gene in methicillin-resistant staphylococci by enzymatic detection of polymerase chain reaction products. J Clin Microbiol 1992; 30:1728.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/26\" class=\"nounderline abstract_t\">Unal S, Hoskins J, Flokowitsch JE, et al. Detection of methicillin-resistant staphylococci by using the polymerase chain reaction. J Clin Microbiol 1992; 30:1685.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/27\" class=\"nounderline abstract_t\">Horstkotte MA, Knobloch JK, Rohde H, Mack D. Rapid detection of methicillin resistance in coagulase-negative staphylococci by a penicillin-binding protein 2a-specific latex agglutination test. J Clin Microbiol 2001; 39:3700.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/28\" class=\"nounderline abstract_t\">Zbinden R, Ritzler M, Ritzler E, Berger-B&auml;chi B. Detection of penicillin-binding protein 2a by rapid slide latex agglutination test in coagulase-negative staphylococci. J Clin Microbiol 2001; 39:412.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/29\" class=\"nounderline abstract_t\">Hussain Z, Stoakes L, Garrow S, et al. Rapid detection of mecA-positive and mecA-negative coagulase-negative staphylococci by an anti-penicillin binding protein 2a slide latex agglutination test. J Clin Microbiol 2000; 38:2051.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/30\" class=\"nounderline abstract_t\">Udo EE, Mokadas EM, Al-Haddad A, et al. Rapid detection of methicillin resistance in staphylococci using a slide latex agglutination kit. Int J Antimicrob Agents 2000; 15:19.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/31\" class=\"nounderline abstract_t\">Chambers HF. Methicillin-resistant staphylococci. Clin Microbiol Rev 1988; 1:173.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/32\" class=\"nounderline abstract_t\">Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987; 316:927.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/33\" class=\"nounderline abstract_t\">Sanyal D, Johnson AP, George RC, et al. Peritonitis due to vancomycin-resistant Staphylococcus epidermidis. Lancet 1991; 337:54.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/34\" class=\"nounderline abstract_t\">Veach LA, Pfaller MA, Barrett M, et al. Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. J Clin Microbiol 1990; 28:2064.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/35\" class=\"nounderline abstract_t\">Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, et al. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 1998; 42:199.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/36\" class=\"nounderline abstract_t\">Cui L, Ma X, Sato K, et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 2003; 41:5.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/37\" class=\"nounderline abstract_t\">Sieradzki K, Tomasz A. Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J Bacteriol 1999; 181:7566.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/38\" class=\"nounderline abstract_t\">Sieradzki K, Pinho MG, Tomasz A. Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus. J Biol Chem 1999; 274:18942.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/39\" class=\"nounderline abstract_t\">Nunes AP, Teixeira LM, Iorio NL, et al. Heterogeneous resistance to vancomycin in Staphylococcus epidermidis, Staphylococcus haemolyticus and Staphylococcus warneri clinical strains: characterisation of glycopeptide susceptibility profiles and cell wall thickening. Int J Antimicrob Agents 2006; 27:307.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/40\" class=\"nounderline abstract_t\">Dunne WM Jr, Qureshi H, Pervez H, Nafziger DA. Staphylococcus epidermidis with intermediate resistance to vancomycin: elusive phenotype or laboratory artifact? Clin Infect Dis 2001; 33:135.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/41\" class=\"nounderline abstract_t\">Wong SS, Ho PL, Woo PC, Yuen KY. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 1999; 29:760.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/42\" class=\"nounderline abstract_t\">Gu B, Kelesidis T, Tsiodras S, et al. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 2013; 68:4.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/43\" class=\"nounderline abstract_t\">Kelly S, Collins J, Maguire M, et al. An outbreak of colonization with linezolid-resistant Staphylococcus epidermidis in an intensive therapy unit. J Antimicrob Chemother 2008; 61:901.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/44\" class=\"nounderline abstract_t\">Rybak MJ, Cappelletty DM, Moldovan T, et al. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 1998; 42:721.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/45\" class=\"nounderline abstract_t\">Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis 2000; 30:146.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/46\" class=\"nounderline abstract_t\">Antony SJ, Diaz-Vasquez E, Stratton C. Clinical experience with linezolid in the treatment of resistant gram-positive infections. J Natl Med Assoc 2001; 93:386.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/47\" class=\"nounderline abstract_t\">Saravolatz LD, Stein GE, Johnson LB. Telavancin: a novel lipoglycopeptide. Clin Infect Dis 2009; 49:1908.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/48\" class=\"nounderline abstract_t\">Kratzer C, Rabitsch W, Hirschl AM, et al. In vitro activity of daptomycin and tigecycline against coagulase-negative staphylococcus blood isolates from bone marrow transplant recipients. Eur J Haematol 2007; 79:405.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/49\" class=\"nounderline abstract_t\">Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). Clin Microbiol Infect 2006; 12:844.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/50\" class=\"nounderline abstract_t\">Flamm RK, Sader HS, Farrell DJ, Jones RN. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program. Antimicrob Agents Chemother 2012; 56:2933.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/51\" class=\"nounderline abstract_t\">Flamm RK, Sader HS, Farrell DJ, Jones RN. Ceftaroline potency among 9 US Census regions: report from the 2010 AWARE Program. Clin Infect Dis 2012; 55 Suppl 3:S194.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/52\" class=\"nounderline abstract_t\">Ho TT, Cadena J, Childs LM, et al. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 2012; 67:1267.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/53\" class=\"nounderline abstract_t\">Rose WE, Schulz LT, Andes D, et al. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 2012; 56:5296.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/54\" class=\"nounderline abstract_t\">Sakoulas G, Moise PA, Casapao AM, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther 2014; 36:1317.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/55\" class=\"nounderline abstract_t\">Aldridge KE, Schiro DD, Varner LM. In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin, by two methods. Antimicrob Agents Chemother 1992; 36:854.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/56\" class=\"nounderline abstract_t\">Eliopoulos GM. Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci. Eur J Clin Microbiol Infect Dis 2005; 24:826.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/57\" class=\"nounderline abstract_t\">Rubinstein E, Bompart F. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential. J Antimicrob Chemother 1997; 39 Suppl A:139.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/58\" class=\"nounderline abstract_t\">Stein A, Bataille JF, Drancourt M, et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998; 42:3086.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/59\" class=\"nounderline abstract_t\">Levitz RE, Quintiliani R. Trimethoprim-sulfamethoxazole for bacterial meningitis. Ann Intern Med 1984; 100:881.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/60\" class=\"nounderline abstract_t\">Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117:390.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/61\" class=\"nounderline abstract_t\">Frame PT, McLaurin RL. Treatment of CSF shunt infections with intrashunt plus oral antibiotic therapy. J Neurosurg 1984; 60:354.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/62\" class=\"nounderline abstract_t\">Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 2015; 132:1435.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/63\" class=\"nounderline abstract_t\">Archer GL, Johnston JL. Self-transmissible plasmids in staphylococci that encode resistance to aminoglycosides. Antimicrob Agents Chemother 1983; 24:70.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/64\" class=\"nounderline abstract_t\">Archer GL, Scott J. Conjugative transfer genes in staphylococcal isolates from the United States. Antimicrob Agents Chemother 1991; 35:2500.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/65\" class=\"nounderline abstract_t\">Mandell GL, Moorman DR. Treatment of experimental staphylococcal infections: effect of rifampin alone and in combination on development of rifampin resistance. Antimicrob Agents Chemother 1980; 17:658.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/66\" class=\"nounderline abstract_t\">Howden BP, Grayson ML. Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 2006; 42:394.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/67\" class=\"nounderline abstract_t\">Trucksis M, Hooper DC, Wolfson JS. Emerging resistance to fluoroquinolones in staphylococci: an alert. Ann Intern Med 1991; 114:424.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/68\" class=\"nounderline abstract_t\">Fraimow HS. Systemic antimicrobial therapy in osteomyelitis. Semin Plast Surg 2009; 23:90.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/69\" class=\"nounderline abstract_t\">Metzler K, Hansen GM, Hedlin P, et al. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 2004; 24:161.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/70\" class=\"nounderline abstract_t\">Firsov AA, Vostrov SN, Lubenko IY, et al. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:1604.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/71\" class=\"nounderline abstract_t\">Schimel AM, Miller D, Flynn HW. Evolving fluoroquinolone resistance among coagulase-negative Staphylococcus isolates causing endophthalmitis. Arch Ophthalmol 2012; 130:1617.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/72\" class=\"nounderline abstract_t\">Bispo PJ, Alfonso EC, Flynn HW, Miller D. Emerging 8-methoxyfluoroquinolone resistance among methicillin-susceptible Staphylococcus epidermidis isolates recovered from patients with endophthalmitis. J Clin Microbiol 2013; 51:2959.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/73\" class=\"nounderline abstract_t\">H&oslash;iby N, Jarl&oslash;v JO, Kemp M, et al. Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis. Lancet 1997; 349:167.</a></li><li><a href=\"https://www.uptodate.com/contents/infection-due-to-coagulase-negative-staphylococci-treatment/abstract/74\" class=\"nounderline abstract_t\">H&oslash;iby N, Johansen HK. Ciprofloxacin in sweat and antibiotic resistance. The Copenhagen Study Group on Antibiotics in Sweat. Lancet 1995; 346:1235.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3154 Version 16.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H6287571\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H6286044\" id=\"outline-link-H6286044\">ANTIMICROBIAL SUSCEPTIBILITY</a><ul><li><a href=\"#H2\" id=\"outline-link-H2\">Methicillin</a><ul><li><a href=\"#H6285704\" id=\"outline-link-H6285704\">- Microbiology</a></li><li><a href=\"#H6285711\" id=\"outline-link-H6285711\">- Epidemiology</a></li><li><a href=\"#H6285719\" id=\"outline-link-H6285719\">- Laboratory detection</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">Vancomycin</a></li><li><a href=\"#H6286944\" id=\"outline-link-H6286944\">Other resistance</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">TREATMENT</a><ul><li><a href=\"#H6286959\" id=\"outline-link-H6286959\">Choice of therapy</a></li><li><a href=\"#H6286966\" id=\"outline-link-H6286966\">Duration</a></li></ul></li><li><a href=\"#H6287571\" id=\"outline-link-H6287571\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antimicrobial-therapy-of-native-valve-endocarditis\" class=\"medical medical_review\">Antimicrobial therapy of native valve endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infection-due-to-coagulase-negative-staphylococci-clinical-manifestations\" class=\"medical medical_review\">Infection due to coagulase-negative staphylococci: Clinical manifestations</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infection-due-to-coagulase-negative-staphylococci-epidemiology-microbiology-and-pathogenesis\" class=\"medical medical_review\">Infection due to coagulase-negative staphylococci: Epidemiology, microbiology, and pathogenesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-microbiology\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus (MRSA): Microbiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-antibacterial-susceptibility-testing\" class=\"medical medical_review\">Overview of antibacterial susceptibility testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin\" class=\"medical medical_review\">Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=staphylococcus-lugdunensis\" class=\"medical medical_review\">Staphylococcus lugdunensis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-intravascular-catheter-related-infections\" class=\"medical medical_review\">Treatment of intravascular catheter-related infections</a></li></ul></div></div>","javascript":null}